Yu‐Nien Sun

864 total citations
30 papers, 702 citations indexed

About

Yu‐Nien Sun is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yu‐Nien Sun has authored 30 papers receiving a total of 702 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 10 papers in Radiology, Nuclear Medicine and Imaging and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yu‐Nien Sun's work include Monoclonal and Polyclonal Antibodies Research (10 papers), Multiple Myeloma Research and Treatments (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Yu‐Nien Sun is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), Multiple Myeloma Research and Treatments (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Yu‐Nien Sun collaborates with scholars based in United States, Belgium and Spain. Yu‐Nien Sun's co-authors include René Bruno, Jianfeng Lü, Alan Kivitz, Debra Zack, Susanna Proudman, Liyun Ni, Francis X. Burch, Christopher Banfield, Michael S. Vincent and John P. Donohue and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Yu‐Nien Sun

30 papers receiving 688 citations

Peers

Countries citing papers authored by Yu‐Nien Sun

Since Specialization

Citations

This map shows the geographic impact of Yu‐Nien Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu‐Nien Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu‐Nien Sun more than expected).

Fields of papers citing papers by Yu‐Nien Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu‐Nien Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu‐Nien Sun. The network helps show where Yu‐Nien Sun may publish in the future.

Co-authorship network of co-authors of Yu‐Nien Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Yu‐Nien Sun. A scholar is included among the top collaborators of Yu‐Nien Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu‐Nien Sun. Yu‐Nien Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non‐Small Cell Lung Cancer 2023 ·Clinical Pharmacology & Therapeutics ·Nahor Haddish‐Berhane, (unknown), Alberto Russu, Meena Thayu, Roland E. Knoblauch, (unknown), John Xie, (unknown), Yu‐Nien Sun, Honghui Zhou	5
2	Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma 2022 ·Targeted Oncology ·Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson, Xuewen Ma, Shoba Shetty, Tong‐Yuan Yang, Brandi Hilder, Qun Jiao, (unknown), Homer Adams, Yu‐Nien Sun, Amarnath Sharma, Jennifer Smit, Jeffrey R. Infante, Jenna D. Goldberg, Yusri Elsayed	10
3	Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis 2021 ·The Journal of Clinical Pharmacology ·Man Luo, Peijuan Zhu, Ivo Nnane, Yuan Xiong, Giampaolo Merlini, Raymond L. Comenzo, Efstathios Kastritis, Ashutosh Wechalekar, Brendan M. Weiss, NamPhuong Tran, Xiang Qin, Jessica Vermeulen, Amarnath Sharma, Yu‐Nien Sun, Honghui Zhou	8
4	Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses 2020 ·Advances in Therapy ·Xu Steven Xu, Philippe Moreau, Saad Z. Usmani, Sagar Lonial, Andrzej Jakubowiak, Albert Oriol, Amrita Krishnan, Joan Bladé, Man Luo, Yu‐Nien Sun, Honghui Zhou, Ivo Nnane, William Deraedt, Ming Qi, Jon Ukropec, Pamela L. Clemens	9
5	Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study 2015 ·The Breast ·Véronique Dièras, Hans Wildiers, Jacek Jassem, Luc Dirix, Jean‐Paul Guastalla, Petri Bono, Sara A. Hurvitz, Anthony Gonçalvès, Gilles Romieu, Steven Limentani, Guy Jérusalem, K C Lakshmaiah, Henri Roché, Pedro Sánchez‐Rovira, Tadeusz Pieńkowski, Miguel Ángel Seguí, Li Ai, Yu‐Nien Sun, Cheryl A. Pickett, Dennis J. Slamon	40
6	Pharmacokinetic drug–drug interaction assessment of peptibody trebananib in combination with chemotherapies 2015 ·Cancer Chemotherapy and Pharmacology ·Benjamin Wu, (unknown), Erik Rasmussen, Lei Zhou, Teresa Wong, (unknown), Mark Ma, Jessica Bo Li Lu, Érick Gamelin, Cheryl A. Pickett, Yu‐Nien Sun	1
7	FLT3 and CDK4/6 inhibitors: Signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia 2014 ·Journal of Pharmacokinetics and Pharmacodynamics ·Yaping Zhang, Cheng‐Pang Hsu, Jianfeng Lü, (unknown), Yu‐Nien Sun, Ji Ma, Guifen Xu, Yilong Zhang, Yang Xu, Margaret F. Weidner, (unknown), David Z. D’Argenio	9
8	Pharmacokinetics of Peptide–Fc Fusion Proteins 2013 ·Journal of Pharmaceutical Sciences ·(unknown), Yu‐Nien Sun	62
9	Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab 2012 ·Journal of Pharmacokinetics and Pharmacodynamics ·(unknown), Cheng‐Pang Hsu, Jianfeng Lü, Yu‐Nien Sun, Shuang Bai, (unknown), David Z. D’Argenio	5
10	AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney 2012 ·Cancer ·Brian Rini, Cezary Szczylik, Nizar M. Tannir, P. Koralewski, Piotr Tomczak, Andrzej Deptała, Luc Dirix, Mayer Fishman, Rodryg Ramlau, Alain Ravaud, Wojciech Rogowski, (unknown), Yu‐Nien Sun, Michael Bass, Markus Puhlmann, Bernard Escudier	87
11	Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection 2011 ·Cancer Chemotherapy and Pharmacology ·Jianfeng Lü, Erik Rasmussen, Beth Y. Karlan, Ignace Vergote, Lynn Navale, (unknown), (unknown), Daniel E. Stepan, David M. Weinreich, Yu‐Nien Sun	34
12	Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study 2011 ·BMC Cancer ·Dusan Kotasek, Niall C. Tebbutt, Jayesh Desai, Stephen Welch, Lillian L. Siu, Sheryl McCoy, Yu‐Nien Sun, Jessica Johnson, Adeboye H. Adewoye, Timothy Price	8
13	Investigation of the Pharmacokinetics of Romiplostim in Rodents with a Focus on the Clearance Mechanism 2011 ·Pharmaceutical Research ·Yow‐Ming Wang, (unknown), Teresa Wong, (unknown), (unknown), Yu‐Nien Sun	31
14	Investigation of the Mechanism of Clearance of AMG 386, a Selective Angiopoietin-1/2 Neutralizing Peptibody, in Splenectomized, Nephrectomized, and FcRn Knockout Rodent Models 2011 ·Pharmaceutical Research ·Benjamin Wu, Jessica Johnson, (unknown), (unknown), (unknown), Yu‐Nien Sun	12
15	Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients 2010 ·Cancer Chemotherapy and Pharmacology ·Jianfeng Lü, Laurent Claret, Liviawati Sutjandra, (unknown), (unknown), René Bruno, Yu‐Nien Sun	27
16	Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors 2010 ·Cancer Chemotherapy and Pharmacology ·Yasuhito Fujisaka, Yasuhide Yamada, Noboru Yamamoto, Toshio Shimizu, Yutaka Fujiwara, Kazuhiko Yamada, Tomohide Tamura, Hiroyuki Watanabe, Yu‐Nien Sun, Michael Bass, (unknown)	19
17	A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology 2010 ·The Journal of Clinical Pharmacology ·René Bruno, Jianfeng Lu, Yu‐Nien Sun, Laurent Claret	20
18	Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer 2010 ·Cancer Chemotherapy and Pharmacology ·Laurent Claret, Jianfeng Lü, Yu‐Nien Sun, René Bruno	27
19	PD3-3-7: Safety and Pharmacokinetics (PK) of AMG 706 With Carboplatin/Paclitaxel (C/P) and/or Panitumumab for the treatment of patients with advanced non-small cell lung cancer (NSCLC) 2007 ·Journal of Thoracic Oncology ·George R. Blumenschein, Alan Sandler, Timothy J. O’Rourke, Jesse McGreivy, Yu‐Nien Sun, Yining Ye, (unknown), Joe Stephenson	7
20	Population Pharmacokinetics of Efalizumab (Humanized Monoclonal Anti‐CD11a Antibody) Following Long‐Term Subcutaneous Weekly Dosing in Psoriasis Subjects 2005 ·The Journal of Clinical Pharmacology ·Yu‐Nien Sun, Jianfeng Lü, Amita Joshi, Peter G. Compton, Paul Kwon, René Bruno	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact